 BOULDER, Colo., Sept. 17, 2021 GLOBE NEWSWIRE -- Brickell Biotech, Inc. Brickell Nasdaq: BBI, a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it is scheduled to host a key opinion leader KOL webinar on DYRK1A Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A, which is believed to play a key role in autoimmune and inflammatory diseases, on Friday, September 24, 2021 at 10:00 a.m. EDT. 